Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: Otto Erik
Tweet
Share
E-mail|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 3)*
|
Chemomab Therapeutics Ltd. (Name of Issuer) |
American Depository Shares, each of which represent twenty ordinary shares, no par value (Title of Class of Securities) |
(CUSIP Number) |
08/10/2026 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
| Rule 13d-1(b) |
| Rule 13d-1(c) |
| Rule 13d-1(d) |
SCHEDULE 13G
|
| CUSIP No. |
| 1 | Names of Reporting Persons
Otto Erik | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b) | ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CANADA (FEDERAL LEVEL)
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
90,000.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
1.2 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: *Percent of class represented by Row (11) based on 7,200,377 ADSs outstanding as of May 14th, 2026 (As provided by the Issuer)
SCHEDULE 13G
|
| Item 1. | |
| (a) | Name of issuer:
Chemomab Therapeutics Ltd. |
| (b) | Address of issuer's principal executive offices:
KIRYAT ATIDIM, BUILDING 7, TEL AVIV, ISRAEL, 6158101 |
| Item 2. | |
| (a) | Name of person filing:
Erik Otto |
| (b) | Address or principal business office or, if none, residence:
144 West Oakview Place, San Antonio, TX 78209 |
| (c) | Citizenship:
Canada |
| (d) | Title of class of securities:
American Depository Shares, each of which represent twenty ordinary shares, no par value |
| (e) | CUSIP No.:
|
| Item 4. | Ownership |
| (a) | Amount beneficially owned:
90000 |
| (b) | Percent of class:
1.2 %
|
| (c) | Number of shares as to which the person has:
|
| (i) Sole power to vote or to direct the vote:
90000 | |
| (ii) Shared power to vote or to direct the vote:
| |
| (iii) Sole power to dispose or to direct the disposition of:
90000 | |
| (iv) Shared power to dispose or to direct the disposition of:
| |
| Item 5. | Ownership of 5 Percent or Less of a Class. |
Ownership of 5 percent or less of a class
| |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
Not Applicable
| |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not Applicable
| |
| Item 8. | Identification and Classification of Members of the Group. |
Not Applicable
| |
| Item 9. | Notice of Dissolution of Group. |
Not Applicable
|
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
13GSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
